vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and INSTEEL INDUSTRIES INC (IIIN). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $159.9M, roughly 1.5× INSTEEL INDUSTRIES INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 4.7%, a 6.4% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 23.3%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-2.2M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 12.0%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Insteel Industries Inc is a leading U.S. manufacturer of steel reinforcing products including welded wire reinforcement and steel fibers. It primarily serves non-residential construction, infrastructure, and precast concrete segments across North America, delivering high-performance reinforcement solutions for various construction projects.
ANIP vs IIIN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $159.9M |
| Net Profit | $27.5M | $7.6M |
| Gross Margin | — | 11.3% |
| Operating Margin | 14.1% | 6.0% |
| Net Margin | 11.1% | 4.7% |
| Revenue YoY | 29.6% | 23.3% |
| Net Profit YoY | 367.5% | 602.4% |
| EPS (diluted) | $1.14 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $159.9M | ||
| Q3 25 | $227.8M | $177.4M | ||
| Q2 25 | $211.4M | $179.9M | ||
| Q1 25 | $197.1M | $160.7M | ||
| Q4 24 | $190.6M | $129.7M | ||
| Q3 24 | $148.3M | $134.3M | ||
| Q2 24 | $138.0M | $145.8M | ||
| Q1 24 | $137.4M | $127.4M |
| Q4 25 | $27.5M | $7.6M | ||
| Q3 25 | $26.6M | $14.6M | ||
| Q2 25 | $8.5M | $15.2M | ||
| Q1 25 | $15.7M | $10.2M | ||
| Q4 24 | $-10.3M | $1.1M | ||
| Q3 24 | $-24.2M | $4.7M | ||
| Q2 24 | $-2.3M | $6.6M | ||
| Q1 24 | $18.2M | $6.9M |
| Q4 25 | — | 11.3% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 17.1% | ||
| Q1 25 | — | 15.3% | ||
| Q4 24 | — | 7.3% | ||
| Q3 24 | — | 9.1% | ||
| Q2 24 | — | 10.6% | ||
| Q1 24 | — | 12.3% |
| Q4 25 | 14.1% | 6.0% | ||
| Q3 25 | 15.9% | 10.8% | ||
| Q2 25 | 6.6% | 11.0% | ||
| Q1 25 | 13.3% | 8.3% | ||
| Q4 24 | -2.3% | 1.1% | ||
| Q3 24 | -13.8% | 4.5% | ||
| Q2 24 | 3.7% | 6.0% | ||
| Q1 24 | 14.8% | 7.0% |
| Q4 25 | 11.1% | 4.7% | ||
| Q3 25 | 11.7% | 8.2% | ||
| Q2 25 | 4.0% | 8.4% | ||
| Q1 25 | 8.0% | 6.4% | ||
| Q4 24 | -5.4% | 0.8% | ||
| Q3 24 | -16.3% | 3.5% | ||
| Q2 24 | -1.7% | 4.5% | ||
| Q1 24 | 13.2% | 5.4% |
| Q4 25 | $1.14 | $0.39 | ||
| Q3 25 | $1.13 | $0.74 | ||
| Q2 25 | $0.36 | $0.78 | ||
| Q1 25 | $0.69 | $0.52 | ||
| Q4 24 | $-0.45 | $0.06 | ||
| Q3 24 | $-1.27 | $0.24 | ||
| Q2 24 | $-0.14 | $0.34 | ||
| Q1 24 | $0.82 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $15.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $358.8M |
| Total Assets | $1.4B | $456.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $15.6M | ||
| Q3 25 | $262.6M | $38.6M | ||
| Q2 25 | $217.8M | $53.7M | ||
| Q1 25 | $149.8M | $28.4M | ||
| Q4 24 | $144.9M | $36.0M | ||
| Q3 24 | $145.0M | $111.5M | ||
| Q2 24 | $240.1M | $97.7M | ||
| Q1 24 | $228.6M | $83.9M |
| Q4 25 | $540.7M | $358.8M | ||
| Q3 25 | $505.8M | $371.5M | ||
| Q2 25 | $436.8M | $356.2M | ||
| Q1 25 | $418.6M | $341.4M | ||
| Q4 24 | $403.7M | $331.6M | ||
| Q3 24 | $405.9M | $350.9M | ||
| Q2 24 | $455.8M | $346.0M | ||
| Q1 24 | $452.0M | $340.6M |
| Q4 25 | $1.4B | $456.1M | ||
| Q3 25 | $1.4B | $462.6M | ||
| Q2 25 | $1.3B | $471.9M | ||
| Q1 25 | $1.3B | $421.9M | ||
| Q4 24 | $1.3B | $404.7M | ||
| Q3 24 | $1.3B | $422.6M | ||
| Q2 24 | $920.8M | $414.6M | ||
| Q1 24 | $914.5M | $397.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-701.0K |
| Free Cash FlowOCF − Capex | $29.1M | $-2.2M |
| FCF MarginFCF / Revenue | 11.8% | -1.4% |
| Capex IntensityCapex / Revenue | 0.5% | 0.9% |
| Cash ConversionOCF / Net Profit | 1.10× | -0.09× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $439.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-701.0K | ||
| Q3 25 | $44.1M | $-17.0M | ||
| Q2 25 | $75.8M | $28.5M | ||
| Q1 25 | $35.0M | $-3.3M | ||
| Q4 24 | $15.9M | $19.0M | ||
| Q3 24 | $12.5M | $16.2M | ||
| Q2 24 | $17.4M | $18.8M | ||
| Q1 24 | $18.3M | $1.4M |
| Q4 25 | $29.1M | $-2.2M | ||
| Q3 25 | $38.0M | $-18.7M | ||
| Q2 25 | $71.8M | $26.9M | ||
| Q1 25 | $32.5M | $-5.5M | ||
| Q4 24 | $13.5M | $16.3M | ||
| Q3 24 | $7.7M | $14.5M | ||
| Q2 24 | $13.0M | $15.5M | ||
| Q1 24 | $13.7M | $-580.0K |
| Q4 25 | 11.8% | -1.4% | ||
| Q3 25 | 16.7% | -10.6% | ||
| Q2 25 | 34.0% | 15.0% | ||
| Q1 25 | 16.5% | -3.5% | ||
| Q4 24 | 7.1% | 12.6% | ||
| Q3 24 | 5.2% | 10.8% | ||
| Q2 24 | 9.4% | 10.7% | ||
| Q1 24 | 10.0% | -0.5% |
| Q4 25 | 0.5% | 0.9% | ||
| Q3 25 | 2.7% | 1.0% | ||
| Q2 25 | 1.9% | 0.9% | ||
| Q1 25 | 1.3% | 1.4% | ||
| Q4 24 | 1.3% | 2.1% | ||
| Q3 24 | 3.2% | 1.3% | ||
| Q2 24 | 3.2% | 2.2% | ||
| Q1 24 | 3.3% | 1.5% |
| Q4 25 | 1.10× | -0.09× | ||
| Q3 25 | 1.66× | -1.17× | ||
| Q2 25 | 8.87× | 1.88× | ||
| Q1 25 | 2.23× | -0.32× | ||
| Q4 24 | — | 17.56× | ||
| Q3 24 | — | 3.48× | ||
| Q2 24 | — | 2.86× | ||
| Q1 24 | 1.00× | 0.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
IIIN
| Welded Wire Reinforcement | $108.4M | 68% |
| PC Strand | $51.6M | 32% |
